Oncologie en Hematologie

Alvleesklierkanker

• Olaparib^IND

Baarmoederhalskanker

• Axalimogene filolisbac

Blaaskanker

• Atezolizumab^IND
• Durvalumab
• Durvalumab / Tremelimumab

• Pembrolizumab

  • 1L bladder carcinoma stage III/IV, not cisplatin-eligible.^IND
  • KEYTRUDA als monotherapie is geïndiceerd voor de behandeling van lokaal gevorderd of gemetastaseerd urotheelcarcinoom bij volwassenen die eerder platinumbevattende chemotherapie hebben ondergaan. KEYTRUDA als monotherapie is geïndiceerd voor de behandeling van lokaal gevorderd of gemetastaseerd urotheelcarcinoom bij volwassenen die niet in aanmerking komen voor cisplatinebevattende chemotherapie.
• Ramucirumab^IND

Borstkanker

• Abemaciclib
• Alpelisib
• Atezolizumab^IND
• Fulvestrant
• Neratinib
• Olaparib^IND

• Pembrolizumab

  • Breast cancer, metastatic, triple negative, 1L.^IND
  • 2/3L Triple negative metastatic breast cancer^IND
  • Triple Negative Breast Cancer - Neoadjuvant^IND
• Pertuzumab

• Ribociclib

  • Behandeling van HR+/HER2- lokaal gevorderd of gemetastaseerd mammacarcinoom in combinatie met een aromataseremmer of fulvestrant. In pre- of perimenopauzale vrouwen dient de endocriene therapie gecombineerd te worden met een ‘luteinizing hormone-releasing hormone’ (LHRH) agonist.^IND
  • Breast cancer, advanced metastatic, HR+ and HER2-, in combination with fulvestrant, postmenopausal women and men, 1L en 2L.^IND
• Talazoparib
• Trastuzumab
• Trastuzumab emtansine^IND

• Veliparib

  • Breast cancer; HER2-negative metastatic or locally advanced unresectable BRCA-associated - first to third-line in combination with carboplatin and paclitaxel.
  • Breast cancer; early-stage triple-negative - neoadjuvant therapy with carboplatin

Borstvlieskanker

• Nintedanib
• Nivolumab^IND

Darmkanker

• Atezolizumab^IND
• Encorafenib^IND
• Nivolumab

Eierstokkanker

• Avelumab^IND
• Niraparib (tosylate monohydrate)

• Olaparib

  • Lynparza is geïndiceerd als monotherapie voor de onderhoudsbehandeling van volwassen patiënten met platinasensitief recidief hooggradig epitheliaal ovarium, tuba- of primair peritoneaal carcinoom die een respons (volledige of partiële) vertonen op platinabevattende chemotherapie.
  • Extension of indication to include the use of Lynparza as a montherapy for the maintenance treatment of adult patients with newly diagnosed advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy.^IND
• Olaparib / Cediranib
• Paclitaxel
• Rucaparib
• Veliparib

Graft versus Host

• Ibrutinib
• Itacitinib
• Remestemcel-L

Hematologie overig

• Donor-derived T-lymphocyte enriched leukocyte preparation depleted ex vivo of host-alloreactive T cells.

• Fedratinib

  • Myelofibrosis
  • Polycythemia vera^IND
• Fostamatinib
• Lusutrombopag
• Pacritinib
• Romiplostim
• Ropeginterferon alfa-2b
• Treosulfan

Hemofilie

• Damoctocog alfa pegol
• Emicizumab
• Rurioctocog alfa pegol
• Viable T-cells

Hersenkanker

• Brain cancer vaccine
• Depatuxizumab mafodotin

Hoofd- en halskanker

• Afatinib
• Brilacidin

• Durvalumab

  • Squamous cell carcinoma of the head and neck, 1L PDL 1.
  • Squamous cell carcinoma of the head and neck, 2L

• Durvalumab / Tremelimumab

  • Head and neck (or upper airways tract) cancers; squamous cell carcinoma of head or neck (SCCHN), 2L Durvalumab monotherapy in PDL1-positive tumours or in combination with Tremelimumab for PDL1-negative tumours.
  • Squamous cell carcinoma of the head and neck, 1L PDL 1^IND

• Pembrolizumab

  • Keytruda as monotherapy is indicated for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a ≥ 50% TPS and progressing on or after platinum-containing chemotherapy. (2L)^IND
  • 1L squamous head and neck cancer with PD-L1 expression.^IND

Huidkanker

• Avelumab
• Binimetinib
• Cemiplimab
• Dabrafenib / Trametinib^IND
• Encorafenib
• Lifileucel
• LN-144 (TIL)
• Nivolumab^IND
• Pembrolizumab^IND
• Seviprotimut-L

Leukemie

• Blinatumomab

  • Blincyto is indicated as monotherapy for the treatment of adults with Philadelphia chromosome negative CD19 positive B-precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.^IND
  • Monotherapy for the treatment of paediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B-cell precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation.^IND
  • Relapsed / Refractory Ph+ Adult Acute Lymphoblastic Leukemia (ALL).^IND
• Bosutinib
• Cytarabine / daunorubicin (liposomaal)

• Dasatinib

  • Geïndiceerd voor de behandeling van pediatrische patiënten met nieuw gediagnosticeerde Ph+ CML in de chronische fase (Ph+ CML-CP) of met Ph+ CML-CP die resistent of intolerant zijn voor eerder toegediende geneesmiddelen waaronder imatinib.^IND
  • Extension of Indication to include a paediatric indication for Philadelphia chromosome positive acute lymphoblastic leukaemia for Sprycel.^IND
• Duvelisib
• Enasidenib
• Eryaspase (Asparaginase)
• Gemtuzumab ozogamicin
• Gilteritinib

• Ibrutinib

  • 1L Chronic Lymphatic Leukemia young and fit patients^IND
  • Extension of indication to the existing chronic lymphocytic leukaemia (CLL) indication to include combination use with obinutuzumab for the treatment of adult patients with previously untreated CLL.^IND
• Idelalisib
• Imetelstat
• Inotuzumab ozogamicin
• Luspatercept
• Midostaurin
• Moxetumomab pasudotox
• Nilotinib
• Quizartinib
• Sapacitabine
• Tamibarotene
• Tisagenlecleucel
• Tisagenlecleucel-T
• Venetoclax^IND
• Venetoclax / cytarabine
• Venetoclax in combinatie met rituximab^IND

Leverkanker

• Cabozantinib^IND
• Lenvatinib^IND

• Nivolumab

  • Advanced hepatocellular carcinoma (HCC) - first-line.^IND
  • Hepatocellular carcinoma after sorafenib (liver cancer)
• Ramucirumab^IND
• Regorafenib

Longkanker

• Alectinib
• Anamorelin

• Atezolizumab

  • 1L gemetastaseerd niet-plaveisecel NSCLC icm bevacizumab en chemotherapie^IND
  • For the 1L treatment of patients with metastatic, squamous NSCLC in combination with chemotherapy^IND
  • Extensive-stage small-cell lung cancer, first-line treatment in combination with carboplatin and etoposide. Independent of PD-L1 expression.^IND
  • Tecentriq is als monotherapie geïndiceerd voor de behandeling van volwassen patiënten met lokaal gevorderde of gemetastaseerde niet-kleincellige longkanker (NSCLC) na eerdere behandeling met chemotherapie. Patiënten met EGFR-activerende mutaties of ALK-positieve mutaties moeten ook doelgerichte behandeling hebben ontvangen voor ze Tecentriq krijgen.
  • NSCLC non-squamous 1st line.
• Avelumab
• Brigatinib
• Dacomitinib

• Durvalumab

  • Imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum-based chemoradiation therapy.
  • Non-small cell lung cancer (NSCLC), 1L monotherapy
• Durvalumab / Tremelimumab^IND
• Entrectinib
• Lorlatinib
• Lurbinectedin
• Nivolumab^IND
• Osimertinib^IND

• Pembrolizumab

  • First-line treatment of metastatic non-squamous NSCLC in adults whose tumours have no EGFR or ALK positive mutations in combination with pemetrexed and platinum chemotherapy.^IND
  • Extension of Indication to include, in combination with carboplatin and either paclitaxel or nab-paclitaxel, for the first-line treatment of metastatic squamous NSCLC in adults for Keytruda.^IND
  • Gevorderd (stadium IIIb) of gemetastaseerd 1L NSCLC, ALK-/EGFR- (monotherapie, met een PD-L1 expressie >1%)^IND
• Rociletinib
• Rovalpituzumab tesirine
• Veliparib

Lymfeklierkanker

• Axicabtagene ciloleucel

• Brentuximab vedotin

  • Eerstelijnsbehandeling van patiënten met CD30+ stadium IV Hodgkin Lymfoom in combinatie met AVD (doxorubicin, vinblastine and dacarbazine).^IND
  • Behandeling van volwassen patiënten met CD30-positief cutaan T-cel lymfoom (CTCL) na ten minste 1 eerdere systemische therapie.

• Ibrutinib

  • Follicular lymphoma (FL), relapsed / refractory.^IND
  • Mantle cell lymphoma (MCL), 1L.^IND
  • Marginal zone lymphoma (MZL), relapsed / refractory.^IND
  • Non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma (DLBCL), 1L.^IND
  • Extension of indication to include treatment of adult patients with Waldenström's macroglobulinaemia (WM) in combination with rituximab.^IND

• Lenalidomide

  • Relapsed/refractory follicular lymphoma (FL) en marginal zone lymphoma (MZL) in combinatie met rituximab^IND
  • 1e lijn ABC subtype DLBCL in combinatie met rituximab en CHOP^IND
• Lenalidomide / Rituximab
• Lisocabtagene maraleucel
• Mogamulizumab
• Obinutuzumab
• Plerixafor^IND
• Polatuzumab vedotin
• Tisagenlecleucel
• Tisagenlecleucel-T

Maagkanker

• Atezolizumab
• Masitinib
• Nivolumab^IND
• Pembrolizumab^IND
• Trifluridine / tipiracil^IND

Multipel Myeloma

• Carfilzomib

• Daratumumab

  • Darzalex is indicated in combination with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.^IND
  • Multipel myeloom frontline behandeling in combinatie met Rd voor patienten die niet in aanmerking komen voor een ASCT.^IND
  • Multipel myeloom frontline behandeling in combinatie met VTd fit voor ASCT.^IND
• Denosumab
• Elotuzumab^IND
• GSK2857916
• Isatuximab
• Lenalidomide^IND
• Lenalidomide / bortezomib / dexamethason
• Pembrolizumab
• Plitidepsin
• Pomalidomide / bortezomib / dexamethason^IND

Neuro-endocriene kanker

• L-lysine / L-arginine
• Lutetium (177Lu) oxodotreotide
• Lutetium-177
• Selumetinib
• Telotristat etiprate

Nierkanker

• Atezolizumab^IND
• Avelumab^IND
• Ipilimumab^IND
• Pembrolizumab^IND
• Rocapuldencel-T
• Sunitinib^IND

Onbekend

• MABp1

Oncologie overig

• Entolimod
• Entrectinib
• Erlotinib^G
• Larotrectinib

• Pembrolizumab

  • Unresectable or metastatic solid tumours with a microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) biomarker.^IND
  • 2L advanced esophageal cancer, squamous^IND
• Pexidartinib

Prostaatkanker

• Abiraterone
• Abiraterone / apalutamide

• Apalutamide

  • Gemetastaseerde hormoon-gevoelige, hoog-volume prostaat carcinoom.^IND
  • Niet-gemetastaseerde castratie resistente prostaat carcinoom (hoog risico).
  • Chemo-naieve gemetastaseerde castratie resistente prostaat carcinoom, in combinatie met Abiraterone.
• Cabazitaxel^G
• Darolutamide

• Enzalutamide

  • Adult men with newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in combination with androgen depreviation therapy.^IND
  • De behandeling van volwassen mannen met niet-gemetastaseerd hoogrisico-CRPC (castratieresistent prostaatcarcinoom).^IND
• Olaparib
• Padeliporfin

Schildklierkanker

• Selumetinib^IND